

Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/EP05/000562

International filing date: 18 January 2005 (18.01.2005)

Document type: Certified copy of priority document

Document details: Country/Office: EP
Number: 04100211.4
Filing date: 22 January 2004 (22.01.2004)

Date of receipt at the International Bureau: 24 February 2005 (24.02.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse



Europäisches
Patentamt

European
Patent Office

PCT/EP200 5/ 0 0 0 5 6 2
Office européen
des brevets

17.01.05

Bescheinigung

Certificate

Attestation

Die angehefteten Unterla-
gen stimmen mit der
ursprünglich eingereichten
Fassung der auf dem näch-
sten Blatt bezeichneten
europäischen Patentanmel-
dung überein.

The attached documents
are exact copies of the
European patent application
described on the following
page, as originally filed.

Les documents fixés à
cette attestation sont
conformes à la version
initialement déposée de
la demande de brevet
européen spécifiée à la
page suivante.

Patentanmeldung Nr. Patent application No. Demande de brevet n°

04100211.4

Der Präsident des Europäischen Patentamts;
Im Auftrag

For the President of the European Patent Office

Le Président de l'Office européen des brevets
p.o.

R C van Dijk



Europäisches
Patentamt

European
Patent Office

Office européen
des brevets

PCT/EP200 5/ 0 0 0 5 6 2

18.01.05

Anmeldung Nr:
Application no.: 04100211.4
Demande no:

Anmeldetag:
Date of filing: 22.01.04
Date de dépôt:

Anmelder/Applicant(s)/Demandeur(s):

Akzo Nobel N.V.
Velperweg 76
6824 BM Arnhem
PAYS-BAS

Bezeichnung der Erfindung/Title of the invention/Titre de l'invention:
(Falls die Bezeichnung der Erfindung nicht angegeben ist, siehe Beschreibung.
If no title is shown please refer to the description.
Si aucun titre n'est indiqué se référer à la description.)

LAWSONIA INTRACELLULARIS 101 kD SUBUNIT VACCINE

In Anspruch genommene Priorität(en) / Priority(ies) claimed /Priorité(s)
revendiquée(s)
Staat/Tag/Aktenzeichen/State/Date/File no./Pays/Date/Numéro de dépôt:

Internationale Patentklassifikation/International Patent Classification/
Classification internationale des brevets:

C07K14/00

Am Anmeldetag benannte Vertragsstaaten/Contracting states designated at date of
filing/Etats contractants désignées lors du dépôt:

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL
PT RO SE SI SK TR LI

Lawsonia intracellularis 101 kD subunit vaccine.

The present invention relates i.a. to nucleic acids encoding novel *Lawsonia intracellularis* proteins, to DNA fragments, recombinant DNA molecules and live
5 recombinant carriers comprising these sequences, to host cells comprising such nucleic acids, DNA fragments, recombinant DNA molecules and live recombinant carriers, to proteins encoded by these nucleotide sequences and to their use for the manufacturing of vaccines, to vaccines for combating *Lawsonia intracellularis* infections and methods for the preparation thereof and to diagnostic tests for the detection of *Lawsonia*
10 *intracellularis* antigens and for the detection of antibodies against *Lawsonia intracellularis*.

Porcine proliferative enteropathy (PPE or PE) has become an important disease of the modern pig industry world-wide. The disease affects 15% to 50% of the growing herds
15 and up to 30% of the individual animals in established problem herds. Today annual economical losses have been estimated US\$ 5-10 in extra feed and facility time costs per affected pig. PPE is a group of chronic and acute conditions of widely differing clinical signs (death, pale and anaemic animals, watery, dark or bright red diarrhoea, depression, reduced appetite and reluctance to move, retarded growth and increased FCR). However
20 there are two consistent features. The first, a pathological change only visible at necropsy, is a thickening of the small intestine and colon mucosa. The second is the occurrence of intracytoplasmatic small-curved bacteria in the enterocytes of the affected intestine. These bacteria have now been established as the etiological agent of PPE and have been name *Lawsonia intracellularis*.

25

Over the years *Lawsonia intracellularis* has been found to affect a large group of animals including monkeys, rabbits, ferrets, hamsters, fox, horses, and other animals as diverse as ostrich and emoe. *Lawsonia intracellularis* is a gram-negative, flagellated bacterium that multiplies in eukaryotic enterocytes only and no cell-free culture has been described. In
30 order to persist and multiply in the cell *Lawsonia intracellularis* must penetrate dividing crypt cells. The bacterium associates with the cell membrane and quickly enters the

enterocyte via an entry vacuole. This then rapidly breaks down (within 3 hours) and the bacteria flourish and multiply freely in the cytoplasm. The mechanisms by which the bacteria cause infected cells to fail to mature, continue to undergo mitosis and form hypoplastic crypt cells is not yet understood.

5

The current understanding of *Lawsonia intracellularis* infection, treatment and control of the disease has been hampered by the fact that *Lawsonia intracellularis* can not be cultivated in cell-free media. Although there are reports of successful co-culturing *Lawsonia intracellularis* in rat enterocytes this has not lead to the development of inactivated vaccines for combating *Lawsonia intracellularis*, although there clearly is a need for such vaccines.

10

It is an objective of the present invention to provide a vaccine for combating *Lawsonia intracellularis* infection.

15

It was surprisingly found now, that *Lawsonia intracellularis* produces a novel protein that is capable of inducing protective immunity against *Lawsonia intracellularis*.

The novel protein will be referred to as the 101 kD protein.

20

The amino acid sequence of the novel protein is presented in sequence identifier SEQ ID NO: 2. The gene encoding this protein has been sequenced and its nucleic acid sequence is shown in sequence identifier SEQ ID NO: 1. The gene will also be referred to in the Examples as "gene 2008".

25

It is well-known in the art, that many different nucleic acid sequences can encode one and the same protein. This phenomenon is commonly known as wobble in the second and especially the third base of each triplet encoding an amino acid. This phenomenon can result in a heterology of about 30% for two nucleic acid sequences still encoding the same protein. Therefore, two nucleic acid sequences having a sequence homology of about 70 % can still encode one and the same protein.

30

Thus, one embodiment relates to nucleic acids encoding a *Lawsonia intracellularis* protein and to parts of that nucleic acid that encode an immunogenic fragment of that protein, wherein those nucleic acids or parts thereof have a level of homology with the nucleic acid of which the sequence is given in SEQ ID NO: 1 of at least 90 %.

5

Preferably, the nucleic acid encoding this *Lawsonia intracellularis* protein or the part of said nucleic acid has at least 92 %, preferably 94 %, more preferably 95 % and even more preferably 96% homology with the nucleic acid having the sequence given in SEQ ID NO: 1. Even more preferred is a homology level of 98 % or even 100 %.

10

The level of nucleotide homology can be determined with the computer program "BLAST 2 SEQUENCES" by selecting sub-program: "BLASTN" that can be found at www.ncbi.nlm.nih.gov/blast/bl2seq/bl2.html.

A reference for this program is Tatiana A. Tatusova, Thomas L. Madden FEMS

15 Microbiol. Letters 174: 247-250 (1999). Parameters used are the default parameters: Reward for a match: +1. Penalty for a mismatch: -2. Open gap: 5. Extension gap: 2. Gap x_dropoff: 50.

20 Another approach for deciding if a certain nucleic acid is or is not a nucleic acid according to the invention relates to the question if that certain nucleic acid does hybridise under stringent conditions to nucleic acids having the nucleotide sequence as depicted in SEQ ID NO: 1.

If a nucleic acid hybridises under stringent conditions to the nucleotide sequence as depicted in SEQ ID NO: 1, it is considered to be a nucleic acid according to the

25 invention.

The definition of stringent conditions follows from the formula of Meinkoth and Wahl (1984. Hybridization of nucleic acids immobilized on solid supports. Anal. Biochem. 138: 267-284.)

$T_m = [81.5^{\circ}\text{C} + 16.6(\log M) + 0.41(\%GC) - 0.61(\%\text{formamide}) - 500/L] -$

30 $1^{\circ}\text{C}/1\%\text{mismatch}$

In this formula, M is molarity of monovalent cations; %GC is the percentage of guanosine and cytosine nucleotides in the DNA; L is the length of the hybrid in base pairs.

5

Stringent conditions are those conditions under which nucleic acids or fragments thereof still hybridise, if they have a mismatch of 10% at the most, to the nucleic acid having the sequence depicted in SEQ ID NO: 1.

10 Since the present invention discloses nucleic acids encoding novel *Lawsonia intracellularis* proteins, it is now for the first time possible to obtain these proteins in sufficient quantities. This can e.g. be done by using expression systems to express the genes encoding the proteins.

Therefore, in a more preferred embodiment, the invention relates to DNA fragments
15 comprising a nucleic acid according to the invention. Such DNA fragments can e.g. be plasmids, into which a nucleic acid according to the invention is cloned. Such DNA fragments are e.g. useful for enhancing the amount of DNA for use as a primer, as described below.

20 An essential requirement for the expression of the nucleic acid is an adequate promoter functionally linked to the nucleic acid, so that the nucleic acid is under the control of the promoter. It is obvious to those skilled in the art that the choice of a promoter extends to any eukaryotic, prokaryotic or viral promoter capable of directing gene transcription in cells used as host cells for protein expression.

25 Therefore, an even more preferred form of this embodiment relates to a recombinant DNA molecule comprising a DNA fragment or a nucleic acid according to the invention that is placed under the control of a functionally linked promoter. This can be accomplished by means of e.g. standard molecular biology techniques. (Sambrook, J. and Russell, D.W., Molecular cloning: a laboratory manual, 2001. ISBN 0-87969-577-3).

30 Functionally linked promoters are promoters that are capable of controlling the transcription of the nucleic acids to which they are linked.

- Such a promoter can be a *Lawsonia* promoter e.g. the promoter involved in *in vivo* expression of the gene encoding the 101 kD protein, provided that that promoter is functional in the cell used for expression. It can also be a heterologous promoter. When the host cells are bacteria, useful expression control sequences which may be used
- 5 include the Trp promoter and operator (Goeddel, et al., Nucl. Acids Res., 8, 4057, 1980); the lac promoter and operator (Chang, et al., Nature, 275, 615, 1978); the outer membrane protein promoter (Nakamura, K. and Inoue, M., EMBO J., 1, 771-775, 1982); the bacteriophage lambda promoters and operators (Remaut, E. et al., Nucl. Acids Res., 11, 4677-4688, 1983); the α -amylase (*B. subtilis*) promoter and operator,
- 10 termination sequences and other expression enhancement and control sequences compatible with the selected host cell.
- When the host cell is yeast, useful expression control sequences include, e.g., α -mating factor. For insect cells the polyhedrin or p10 promoters of baculoviruses can be used (Smith, G.E. et al., Mol. Cell. Biol. 3, 2156-65, 1983). When the host cell is of
- 15 mammalian origin illustrative useful expression control sequences include the SV-40 promoter (Berman, P.W. et al., Science, 222, 524-527, 1983) or the metallothionein promoter (Brinster, R.L., Nature, 296, 39-42, 1982) or a heat shock promoter (Voellmy et al., Proc. Natl. Acad. Sci. USA, 82, 4949-53, 1985).
- 20 Bacterial, yeast, fungal, insect and mammalian cell expression systems are very frequently used systems. Such systems are well-known in the art and generally available, e.g. commercially through Invitrogen (www.invitrogen.com), Novagen (www.merckbiosciences.de) or Clontech Laboratories, Inc. 4030 Fabian Way, Palo Alto, California 94303-4607, USA. Next to these expression systems, parasite-based
- 25 expression systems are very attractive expression systems. Such systems are e.g. described in the French Patent Application with Publication number 2 714 074, and in US NTIS Publication No US 08/043109 (Hoffman, S. and Rogers, W.: Public. Date 1 December 1993).
- 30 A still even more preferred form of this embodiment of the invention relates to Live Recombinant Carriers (LRCs) comprising a nucleic acid encoding the 101 kD protein or

an immunogenic fragment thereof according to the invention, a DNA fragment according to the invention or a recombinant DNA molecule according to the invention. Such carriers are e.g. bacteria and viruses. These LRCs are micro-organisms or viruses in which additional genetic information, in this case a nucleic acid encoding the 101 kD protein or an immunogenic fragment thereof according to the invention has been cloned. Animals infected with such LRCs will produce an immunogenic response not only against the immunogens of the carrier, but also against the immunogenic parts of the protein(s) for which the genetic code is additionally cloned into the LRC, e.g. the 101 kD protein.

As an example of bacterial LRCs, attenuated Salmonella strains known in the art can attractively be used.

Live recombinant carrier parasites have i.a. been described by Vermeulen, A. N. (Int. Journ. Parasitol. 28: 1121-1130 (1998))

Also, LRC viruses may be used as a way of transporting the nucleic acid into a target cell. Live recombinant carrier viruses are also called vector viruses. Viruses often used as vectors are Vaccinia viruses (Panicali et al; Proc. Natl. Acad. Sci. USA, 79: 4927 (1982), Herpesviruses (E.P.A. 0473210A2), and Retroviruses (Valerio, D. et al; in Baum, S.J., Dicke, K.A., Lotzova, E. and Pluznik, D.H. (Eds.), Experimental Haematology today - 1988. Springer Verlag, New York: pp. 92-99 (1989)).

The technique of *in vivo* homologous recombination, well-known in the art, can be used to introduce a recombinant nucleic acid into the genome of a bacterium, parasite or virus of choice, capable of inducing expression of the inserted nucleic acid according to the invention in the host animal.

Finally another form of this embodiment of the invention relates to a host cell comprising a nucleic acid encoding a protein according to the invention, a DNA fragment comprising such a nucleic acid or a recombinant DNA molecule comprising such a nucleic acid under the control of a functionally linked promoter. This form also relates to a host cell containing a live recombinant carrier containing a nucleic acid molecule encoding a 101 kD protein or a fragment thereof according to the invention.

A host cell may be a cell of bacterial origin, e.g. *Escherichia coli*, *Bacillus subtilis* and *Lactobacillus* species, in combination with bacteria-based plasmids as pBR322, or bacterial expression vectors as pGEX, or with bacteriophages. The host cell may also be of eukaryotic origin, e.g. yeast-cells in combination with yeast-specific vector molecules, or higher eukaryotic cells like insect cells (Luckow et al; Bio-technology 6: 47-55 (1988)) in combination with vectors or recombinant baculoviruses, plant cells in combination with e.g. Ti-plasmid based vectors or plant viral vectors (Barton, K.A. et al; Cell 32: 1033 (1983), mammalian cells like Hela cells, Chinese Hamster Ovary cells (CHO) or Crandell Feline Kidney-cells, also with appropriate vectors or recombinant viruses.

Another embodiment of the invention relates to the novel proteins and to immunogenic fragments thereof according to the invention.

The concept of immunogenic fragments will be defined below.

One form of this embodiment relates i.a. to *Lawsonia intracellularis* proteins that have an amino acid sequence that is at least 90 % homologous to the amino acid sequence as depicted in SEQ ID NO: 2 and to immunogenic fragments of said protein.

In a preferred form, the embodiment relates to such *Lawsonia intracellularis* proteins that have a sequence homology of at least 92 %, preferably 94 %, more preferably 96 % homology to the amino acid sequence as depicted in SEQ ID NO: 2 and to immunogenic fragments of such proteins.

Even more preferred is a homology level of 98 % or even 100 %.

The level of protein homology can be determined with the computer program "BLAST 2 SEQUENCES" by selecting sub-program: "BLASTP", that can be found at www.ncbi.nlm.nih.gov/blast/bl2seq/bl2.html.

A reference for this program is Tatiana A. Tatusova, Thomas L. Madden FEMS Microbiol. Letters 174: 247-250 (1999). Matrix used: "blosum62". Parameters used are the default parameters:

Open gap: 11. Extension gap: 1. Gap x_dropoff: 50.

5

It will be understood that, for the particular proteins embraced herein, natural variations can exist between individual *Lawsonia intracellularis* strains. These variations may be demonstrated by (an) amino acid difference(s) in the overall sequence or by deletions, substitutions, insertions, inversions or additions of (an) amino acid(s) in said sequence.

10

Amino acid substitutions which do not essentially alter biological and immunological activities, have been described, e.g. by Neurath et al in "The Proteins" Academic Press New York (1979). Amino acid replacements between related amino acids or

15

replacements which have occurred frequently in evolution are, inter alia, Ser/Ala, Ser/Gly, Asp/Gly, Asp/Asn, Ile/Val (see Dayhof, M.D., Atlas of protein sequence and structure, Nat. Biomed. Res. Found., Washington D.C., 1978, vol. 5, suppl. 3). Other amino acid substitutions include Asp/Glu, Thr/Ser, Ala/Gly, Ala/Thr, Ser/Asn, Ala/Val, Thr/Phe, Ala/Pro, Lys/Arg, Leu/Ile, Leu/Val and Ala/Glu. Based on this information, Lipman and Pearson developed a method for rapid and sensitive protein comparison (Science, 227, 1435-1441, 1985) and determining the functional similarity between

20

homologous proteins. Such amino acid substitutions of the exemplary embodiments of this invention, as well as variations having deletions and/or insertions are within the scope of the invention as long as the resulting proteins retain their immune reactivity.

This explains why *Lawsonia intracellularis* proteins according to the invention, when isolated from different field isolates, may have homology levels of about 90 %, while still

25

representing the same protein with the same immunological characteristics. Those variations in the amino acid sequence of a certain protein according to the invention that still provide a protein capable of inducing an immune response against infection with *Lawsonia intracellularis* or at least against the clinical manifestations of the infection are considered as "not essentially influencing the immunogenicity".

30

When a protein is used for e.g. vaccination purposes or for raising antibodies, it is however not necessary to use the whole protein. It is also possible to use a fragment of that protein that is capable, as such or coupled to a carrier such as e.g. KLH, of inducing an immune response against that protein, a so-called immunogenic fragment. An

5 "immunogenic fragment" is understood to be a fragment of the full-length protein that still has retained its capability to induce an immune response in the host, i.e. comprises a B- or T-cell epitope. At this moment, a variety of techniques is available to easily identify DNA fragments encoding antigenic fragments (determinants). The method described by Geysen et al (Patent Application WO 84/03564, Patent Application WO 86/06487, US

10 Patent NR. 4,833,092, Proc. Natl Acad. Sci. 81: 3998-4002 (1984), J. Imm. Meth. 102, 259-274 (1987), the so-called PEPSCAN method is an easy to perform, quick and well-established method for the detection of epitopes; the immunologically important regions of the protein. The method is used world-wide and as such well-known to man skilled in the art. This (empirical) method is especially suitable for the detection of B-cell epitopes.

15 Also, given the sequence of the gene encoding any protein, computer algorithms are able to designate specific protein fragments as the immunologically important epitopes on the basis of their sequential and/or structural agreement with epitopes that are now known. The determination of these regions is based on a combination of the hydrophilicity criteria according to Hopp and Woods (Proc. Natl. Acad. Sci. 78: 38248-3828 (1981)),

20 and the secondary structure aspects according to Chou and Fasman (Advances in Enzymology 47: 45-148 (1987) and US Patent 4,554,101). T-cell epitopes can likewise be predicted from the sequence by computer with the aid of Berzofsky's amphiphilicity criterion (Science 235, 1059-1062 (1987) and US Patent application NTIS US

25 07/005,885). A condensed overview is found in: Shan Lu on common principles: Tibtech 9: 238-242 (1991), Good et al on Malaria epitopes; Science 235: 1059-1062 (1987), Lu for a review; Vaccine 10: 3-7 (1992), Berzowsky for HIV-epitopes; The FASEB Journal 5:2412-2418 (1991).

Therefore, one form of still another embodiment of the invention relates to vaccines

30 capable of protecting pigs against *Lawsonia intracellularis* infection, that comprise a

protein or an immunogenic fragment thereof
above together with a pharmaceutically acceptable

5 Still another embodiment of the present invention
invention for use in a vaccine.

Still another embodiment relates to the use of
manufacturing of a vaccine for combating *L*

10 One way of making a vaccine according to the
the proteins or immunogenic fragments thereof
obtained through mucosal scrapings taken from
however a very time-consuming way of making

15 It is therefore much more convenient to use
encoding the proteins or immunogenic fragments
vaccines. The nucleic acid of the gene encoding
present invention.

20 Such vaccines based upon the expression product
admixing a protein according to the invention
according to the invention with a pharmaceutically

Alternatively, a vaccine according to the invention
25 carriers as described above, capable of expressing
or immunogenic fragments thereof according to the invention
upon a *Salmonella* carrier or a viral carrier injected
respiratory epithelium have the advantage of mimicking
the natural way of infection of *Lawsonia intracellularis*
30 is an advantage since only low amounts of the antigen are required
immunisation.

Vaccines described above all contribute to active vaccination, i.e. the host's immune system is triggered by a protein according to the invention or an immunogenic fragment thereof, to make antibodies against these proteins.

- 5 Alternatively, such antibodies can be raised in e.g. rabbits or can be obtained from antibody-producing cell lines as described below. Such antibodies can then be administered to the host animal. This method of vaccination, passive vaccination, is the vaccination of choice when an animal is already infected, and there is no time to allow the natural immune response to be triggered. It is also the preferred method for
10 vaccinating immune-compromised animals. Administered antibodies against *Lawsonia intracellularis* can in these cases bind directly to the bacteria. This has the advantage that it immediately decreases or stops *Lawsonia intracellularis* growth.

Therefore, one other form of this embodiment of the invention relates to vaccines comprising antibodies against the 101 kD *Lawsonia intracellularis* protein according to
15 the invention.

Vaccines can also be based upon host cells as described above, that comprise the proteins or immunogenic fragments thereof according to the invention.

- 20 An alternative and efficient way of vaccination is direct vaccination with DNA encoding the relevant antigen. Direct vaccination with DNA encoding proteins has been successful for many different proteins. (As reviewed in e.g. Donnelly et al., The Immunologist 2: 20-26 (1993)).

This way of vaccination is very attractive for the vaccination of pigs against *Lawsonia intracellularis* infection.
25

Therefore, still other forms of this embodiment of the invention relate to vaccines comprising nucleic acids encoding a protein according to the invention or immunogenic fragments thereof according to the invention, and to vaccines comprising DNA fragments that comprise such nucleic acids.

- 30 Still other forms of this embodiment relate to vaccines comprising recombinant DNA molecules according to the invention.

DNA vaccines can easily be administered through intradermal application e.g. using a needle-less injector. This way of administration delivers the DNA directly into the cells of the animal to be vaccinated. Amounts of DNA in the microgram range between 1 and 100 µg provide very good results.

5

In a further embodiment, the vaccine according to the present invention additionally comprises one or more antigens derived from other pig pathogenic organisms and viruses, or genetic information encoding such antigens.

Such organisms and viruses are preferably selected from the group of Pseudorabies virus,

10

Porcine influenza virus, Porcine parvo virus, Transmissible gastro-enteritis virus, Rotavirus, *Escherichia coli*, *Erysipelothrix rhusiopathiae*, *Bordetella bronchiseptica*, *Salmonella choleraesuis*, *Haemophilus parasuis*, *Pasteurella multocida*, *Streptococcus suis*, *Mycoplasma hyopneumoniae*, *Brachyspira hyodysenteriae* and *Actinobacillus pleuropneumoniae*.

15

All vaccines according to the present invention comprise a pharmaceutically acceptable carrier. A pharmaceutically acceptable carrier can be e.g. sterile water or a sterile physiological salt solution. In a more complex form the carrier can e.g. be a buffer.

20

Methods for the preparation of a vaccine comprise the admixing of a protein according to the invention, or an immunogenic fragment thereof, and a pharmaceutically acceptable carrier.

25

Vaccines according to the present invention may in a preferred presentation also contain an adjuvant. Adjuvants in general comprise substances that boost the immune response of the host in a non-specific manner. A number of different adjuvants are known in the art. Examples of adjuvants are Freund's Complete and Incomplete adjuvant, vitamin E, non-ionic block polymers, muramyl dipeptides, Quill A(R), mineral oil e.g. Bayol(R) or Markol(R), vegetable oil, and Carbopol(R) (a homopolymer), or Diluvac(R) Forte.

30

The vaccine may also comprise a so-called "vehicle". A vehicle is a compound to which the polypeptide adheres, without being covalently bound to it. Often used vehicle

compounds are e.g. aluminium hydroxide, -phosphate or -oxide, silica, Kaolin, and Bentonite.

A special form of such a vehicle, in which the antigen is partially embedded in the vehicle, is the so-called ISCOM (EP 109.942, EP 180.564, EP 242.380)

5 In addition, the vaccine may comprise one or more suitable surface-active compounds or emulsifiers, e.g. Span or Tween.

Often, the vaccine is mixed with stabilisers, e.g. to protect degradation-prone polypeptides from being degraded, to enhance the shelf-life of the vaccine, or to improve freeze-drying efficiency. Useful stabilisers are i.a. SPGA (Bovarnik et al; J. Bacteriology
10 59: 509 (1950)), carbohydrates e.g. sorbitol, mannitol, trehalose, starch, sucrose, dextran or glucose, proteins such as albumin or casein or degradation products thereof, and buffers, such as alkali metal phosphates.

In addition, the vaccine may be suspended in a physiologically acceptable diluent. It goes without saying, that other ways of adjuvating, adding vehicle compounds or
15 diluents, emulsifying or stabilising a polypeptide are also embodied in the present invention.

Vaccines according to the invention can very suitably be administered in amounts ranging between 1 and 100 micrograms, although smaller doses can in principle be used.
20 A dose exceeding 100 micrograms will, although immunologically very suitable, be less attractive for commercial reasons.

Vaccines based upon live attenuated recombinant carriers, such as the LRC-viruses and bacteria described above can be administered in much lower doses, because they multiply
25 themselves during the infection. Therefore, very suitable amounts would range between 10^3 and 10^9 CFU/PFU for respectively bacteria and viruses.

Many ways of administration can be applied. Oral application is a very attractive way of administration, because the infection is an infection of the digestive tract. A preferred
30 way of oral administration is the packaging of the vaccine in capsules, known and frequently used in the art, that only disintegrate after they have passed the highly acidic

environment of the stomach. Also, the vaccine could be mixed with compounds known in the art for temporarily enhancing the pH of the stomach.

Systemic application is also suitable, e.g. by intramuscular application of the vaccine. If this route is followed, standard procedures known in the art for systemic application are well-suited.

From a point of view of protection against disease, a quick and correct diagnosis of *Lawsonia intracellularis* infection is important.

Therefore it is another objective of this invention to provide diagnostic tools suitable for the detection of *Lawsonia intracellularis* infection.

A diagnostic test for the detection of *Lawsonia intracellularis* antibodies in sera can be e.g. a simple standard sandwich-ELISA-test in which 101 kD protein or antigenic fragments thereof according to the invention are coated to the wall of the wells of an ELISA-plate. A method for the detection of such antibodies is e.g. incubation of 101 kD protein or antigenic fragments thereof with serum from mammals to be tested, followed by e.g. incubation with a labelled antibody against the relevant mammalian antibody. A colour reaction can then reveal the presence or absence of antibodies against *Lawsonia intracellularis*. Another example of a diagnostic test system is e.g. the incubation of a Western blot comprising the 101 kD protein or an antigenic fragment thereof according to the invention, with serum of mammals to be tested, followed by analysis of the blot.

Thus, another embodiment of the present invention relates to diagnostic tests for the detection of antibodies against *Lawsonia intracellularis*. Such tests comprise a protein or a fragment thereof according to the invention.

A diagnostic test based upon the detection of antigenic material of the specific 101 kD protein of *Lawsonia intracellularis* antigens and therefore suitable for the detection of *Lawsonia intracellularis* infection can e.g. also be a standard ELISA test. In one example of such a test the walls of the wells of an ELISA plate are coated with antibodies directed against the 101 kD protein. After incubation with the material to be tested, labelled anti-

Lawsonia intracellularis antibodies are added to the wells. A colour reaction then reveals the presence of antigenic material from *Lawsonia intracellularis*.

Therefore, still another embodiment of the present invention relates to diagnostic tests for the detection of antigenic material of *Lawsonia intracellularis*. Such tests comprise
5 antibodies against a protein or a fragment thereof according to the invention.

The polypeptides or immunogenic fragments thereof according to the invention expressed as characterised above can be used to produce antibodies, which may be polyclonal, monospecific or monoclonal (or derivatives thereof). If polyclonal antibodies are desired,
10 techniques for producing and processing polyclonal sera are well-known in the art (e.g. Mayer and Walter, eds. *Immunochemical Methods in Cell and Molecular Biology*, Academic Press, London, 1987).

Monoclonal antibodies, reactive against the polypeptide according to the invention (or variants or fragments thereof) according to the present invention, can be prepared by
15 immunising inbred mice by techniques also known in the art (Kohler and Milstein, *Nature*, 256, 495-497, 1975).

Methods for large-scale production of antibodies according to the invention are also known in the art. Such methods rely on the cloning of (fragments of) the genetic
20 information encoding the protein according to the invention in a filamentous phage for phage display. Such techniques are described i.a. at the "Antibody Engineering Page" under "filamentous phage display" at <http://aximt1.imt.uni-marburg.de/~rek/aepphage.html>, and in review papers by Cortese, R. et al., (1994) in *Trends Biotechn.* 12: 262-267., by Clackson, T. & Wells, J.A. (1994) in *Trends Biotechn.*
25 12: 173-183, by Marks, J.D. et al., (1992) in *J. Biol. Chem.* 267: 16007-16010, by Winter, G. et al., (1994) in *Annu. Rev. Immunol.* 12: 433-455, and by Little, M. et al., (1994) *Biotechn. Adv.* 12: 539-555. The phages are subsequently used to screen camelid expression libraries expressing camelid heavy chain antibodies. (Muyldermans, S. and Lauwereys, M., *Journ. Molec. Recogn.* 12: 131-140 (1999) and Ghahroudi, M.A. et al.,
30 *FEBS Letters* 414: 512-526 (1997)). Cells from the library that express the desired

antibodies can be replicated and subsequently be used for large scale expression of antibodies.

Examples

Example 1:

Isolation of *Lawsonia intracellularis* from infected porcine ilea.

- 5 *L. intracellularis* infected ilea, confirmed by histopathology and acid-fast Ziehl-Neelsen or Whartin-Starry staining, were collected from pigs died with PE, and stored at -80°C. After thawing *L. intracellularis* bacteria were isolated from mucosal scrapings taken from the infected intestinal wall. The ileal scrapings were homogenized repeatedly in PBS in an omnimixer to release the intracellular bacteria as described by Lawson et al. (Vet.
- 10 Microbiol. 10: 303-323 (1985)). Supernatant obtained after low-speed centrifugation to remove cell debris was filtered through 5.0, 3.0, 1.2, and 0.8 µm filters (Millipore). The filtrate was subsequently centrifuged at 8000 g for 30 min, giving a small pellet of *L. intracellularis* bacteria. These bacteria were further purified using a Percoll gradient. The identity of the purified bacteria was assessed by PCR (Jones et al., J. Clin. Microbiol. 31:
- 15 2611-2615 (1993)) whereas purity of the isolated bacteria (>95%) was assessed by phase contrast microscopy to reveal any contaminating bacteria or gut debris present.

Bacterial strains and plasmids

- L. intracellularis* cells were isolated from infected ileal material as described above.
- 20 *E. coli* strain TOP10F' and the TOPO TA cloning kit, containing plasmid pCR2.1 TOPO TA were purchased from Invitrogen (Groningen, the Netherlands). Stocks of all bacterial strains, containing 30% glycerol, were stored at -70°C.
- Luria Bertani broth (LB) and LB plates were prepared according to standard procedures. When needed plasmids were transformed to *E. coli* TOP10F' competent cells by heat
- 25 shock. *E. coli* cells were made competent using standard methods.

DNA isolation

- In order to obtain highly purified *L. intracellularis* chromosomal DNA, DNA was prepared from bacterial cells using a Biorad chromosomal DNA isolation kit (Biorad,
- 30 Veenendaal, the Netherlands) according to manufacturers instructions. Plasmid DNA and

linear DNA was isolated using Qiagen products according to the protocols provided by the manufacturer.

PCR amplification

5 PCR amplification was performed using a Geneamp 9700 PCR system (Applied Biosystems, California, USA). The PCR was performed with the Expand High Fidelity PCR System (Roche Diagnostics GmbH, Mannheim, Germany). The PCR mixture contained 52 U/ml Expand High Fidelity Enzyme Mix, Expand HF buffer with 2.5 mM MgCl₂, 16 mM dNTPs (Promega, Wisconsin, USA), 20 pmoles of primers and 15 ng
10 chromosomal DNA of *L. intracellularis* as template.

For standard applications (i.e. colony PCR) the PCR mixture contained 20 U/ml Supertaq and Supertaq buffer (HT Biotechnology Ltd, Cambridge, UK), containing 8 mM dNTPs (Promega, Wisconsin, USA), 10 pmoles of primers and 15 ng template.

15 In vitro transcription and translation

In vitro transcription and translation was performed using the Rapid Translation System from Roche Applied Science (Mannheim, FRG) according the manufacturer's protocol. Summarizing, first the knowledge based sequence-optimization tool ProteoExpert RTS E. coli HY was used to design high yield variants of the original gene. This program
20 optimizes the DNA template for the translation step by suggesting mutations in the DNA sequence. Only silent mutations were allowed, leading to identical amino-acid sequences on the protein level. However, changes of up to 8 nucleotides within the first 6 codons were proposed by the ProteoExpert service to give better expression results.

Ten sense and a universal antisense primers, containing a 5' overlapping region of 20
25 nucleotides and 15-38 additional gene-specific nucleotides, were used in 10 different PCR reactions to amplify these variants with purified *L. intracellularis* chromosomal DNA as template. The obtained amplicons were purified from gel and used for the generation of linear expression constructs for cell-free protein expression using the RTS E. coli Linear Template Generation Set, His-tag, to introduce the necessary T7 regulatory
30 elements.

Again the obtained amplicons were purified from gel, and after quantification, the appropriate amount of DNA was used for protein expression analysis in a 50- μ l RTS 100 E. coli HY reaction mixture. Expression was analysed using Western blotting with an anti polyhistidine monoclonal antibody.

- 5 The construct that gave the highest protein yields was ligated to pCR2.1 TOPO TA vector using the TOPO TA cloning kit. The obtained plasmid was used for medium scale protein production using the RTS 500 E. coli HY kit. The samples were analyzed by SDS page and by Western blot.

10 The DNA sequence of the expression vector was confirmed using an ABI 310 automated sequencer (Applied Biosystems, California, USA).

Polyacrylamide gel electrophoresis and western blotting

- SDS-PAGE was performed using 4-12% Bis-Tris gels from the NuPAGE electrophoresis system (Novex, San Diego, USA). Western blotting was performed using semi dry
15 blotting procedures. Western blots were developed using chicken and pig anti-Lawsonia polyclonal serum that was raised against a whole cell preparation in a water:oil=45:55 emulsion. The sera were pre-adsorbed using an equal volume crude cell extracts from BL21 star(DE3) containing vector pLysSrare at 4°C for 4 hours.

20

Results

Cloning of *L. intracellularis* gene 2008

- Sequence analysis of gene 2008 had revealed that the gene encoded a putative N-terminal
25 signal sequence and a C-terminal beta-barrel structure. Both structures are known to be very hydrophobic. Because the RTS system has been found unsuitable for the expression of proteins that contain large hydrophobic regions it was decided to amplify gene 2008 from base 37 to 1958. Expression of this gene fragment resulted in a protein of 63 kD. For the evaluation of the ProteoExpert suggestions, linear DNA templates were generated
30 via PCR using the RTS Linear Template Generation Set. The primers used in these experiments also introduced a His₆-tag at the C-terminus for detection and purification.

The PCR-generated templates were examined for their expression performance using RTS 100 *E. coli* HY Kit. The suggested DNA sequence that gave the highest yields was constructed using primers 2008A6 and 2008B (Table 1) in the first PCR.

The linear expression construct was ligated to pCR2.1 TOPO TA vector and the resulting vector was transformed to *E. coli* TOP10F and incubated o/n at 37°C. Putative transformants were checked for the right plasmid, using colony PCR. The plasmid inserts, of colony PCR positive transformants, were checked by nucleotide sequence analysis. One of the clones that contained a sequence as expected on basis of the cloning strategy was chosen and designated pTOPO2008.

Table 1. Sequence of the degenerated primers used for the amplification of gene 2008.

Primer	Sequence
2008A6	CTTTAAGAAGGAGATATACCATGGCAGATGTAT TTTTCGAAGGCAGAACCGAAAC
2008B	TGATGATGAGAACCCCCCCCATTAAACATACCAAATAGAT

Expression of *L. intracellularis* gene 2008 using RTS technology

Plasmid pTOPO2008 was purified from *E. coli* TOP10F and the appropriate amount of DNA was added to an RTS500 vial. After incubation conform the protocol of the manufacturer, a sample was taken for analysis using SDS-PAGE gel electrophoresis (Fig. 1A). A clear protein band of approximately 63 kDa was observed in sample that had been taken after 30 hours of induction (Fig. 1A, lane 3) in comparison with the control sample (Fig. 1A, lane 2).

The same samples were also analysed by western blot using both pig- and chicken-antiserum. A strong reaction with the 63 kD protein was observed using both the polyclonal pig (Fig 1B, lane 3) and chicken serum (Fig 1C, lane 3).

Concusion: the 63 kD fragment of the protein according to the invention can efficiently be expressed. Moreover, the 63 kD protein fragment is strongly and equally well recognised by both chicken- and pig-antiserum against *Lawsonia intracellularis* cells.

The 101 kD protein according to the invention and the 63 kD protein fragment thereof are important vaccine components for the protection of pigs against *Lawsonia intracellularis* infection.

Legend to the figure.

Fig. 1. Analysis of the expression of *Lawsonia intracellularis* gene 2008 using RTS500
5 technology by SDS-PAGE (A) and Western blotting with polyclonal pig serum (B). Lane
1, molecular weight marker; lane 2, control; lane 3, pET2008
Arrows indicate the location of the expression product.

Claims

- 1) Nucleic acid encoding a 101 kD *Lawsonia intracellularis* protein or a part of said nucleic acid that encodes an immunogenic fragment of said protein, said nucleic acid or said part thereof having at least 90 %, preferably 92 %, more preferably 94 %, even more preferably 96% homology with a nucleic acid having a sequence as depicted in SEQ ID NO: 1
- 2) DNA fragment comprising a nucleic acid according to claim 1.
- 3) Recombinant DNA molecule comprising a nucleic acid according to claim 1 or a DNA fragment according to claim 2, under the control of a functionally linked promoter.
- 4) Live recombinant carrier comprising a nucleic acid according to claim 1, a DNA fragment according to claim 2 or a recombinant DNA molecule according to claim 3.
- 5) Host cell comprising a nucleic acid according to claim 1, a DNA fragment according to claim 2, a recombinant DNA molecule according to claim 3 or a live recombinant carrier according to claim 4.
- 6) A 101 kD *Lawsonia intracellularis* protein, said protein comprising an amino acid sequence that is at least 90 %, preferably 92 %, more preferably 94 %, even more preferably 96 % homologous to the amino acid sequence as depicted in SEQ ID NO: 2, or an immunogenic fragment of said protein.
- 7) *Lawsonia intracellularis* protein according to claim 6 for use in a vaccine.
- 8) Use of a *Lawsonia intracellularis* protein according to claim 6 for the manufacturing of a vaccine for combating *Lawsonia intracellularis* infections.
- 9) Vaccine for combating *Lawsonia intracellularis* infections, characterised in that it comprises a nucleic acid according to claim 1, a DNA fragment according to claim 2, a recombinant DNA molecule according to claim 3, a live recombinant carrier according to claim 4, a host cell according to claim 5 or a protein according to claim 6, and a pharmaceutically acceptable carrier.
- 10) Vaccine according to claim 9, characterised in that it comprises an adjuvant.

- 11) Vaccine according to claim 9 or 10, characterised in that it comprises an additional antigen derived from a virus or micro-organism pathogenic to pigs or genetic information encoding said antigen.
- 12) Vaccine according to claim 11, characterised in that said virus or micro-organism pathogenic to pigs is selected from the group of Pseudorabies virus, Porcine influenza virus, Porcine parvo virus, Transmissible gastro-enteritis virus, Rotavirus, *Escherichia coli*, *Erysipelothrix rhusiopathiae*, *Bordetella bronchiseptica*, *Salmonella choleraesuis*, *Haemophilus parasuis*, *Pasteurella multocida*, *Streptococcus suis*, *Mycoplasma hyopneumoniae*, *Brachyspira hyodysenteriae* and *Actinobacillus pleuropneumoniae*.
- 13) Vaccine for combating *Lawsonia intracellularis* infections, characterised in that it comprises antibodies against a protein according to claim 6.
- 14) Method for the preparation of a vaccine according to claim 9-13, said method comprising the admixing of a nucleic acid according to claim 1, a DNA fragment according to claim 2, a recombinant DNA molecule according to claim 3, a live recombinant carrier according to claim 4, a host cell according to claim 5, a protein according to claim 6, or antibodies against a protein according to claim 6, and a pharmaceutically acceptable carrier.
- 15) Diagnostic test for the detection of antibodies against *Lawsonia intracellularis*, characterised in that said test comprises a protein or a fragment thereof as defined in claim 6.
- 16) Diagnostic test for the detection of antigenic material of *Lawsonia intracellularis*, characterised in that said test comprises antibodies against a protein or a fragment thereof as defined in claim 6.

Abstract

The present invention relates i.a. to nucleic acids encoding novel *Lawsonia intracellularis* proteins. It furthermore relates to DNA fragments, recombinant DNA molecules and live recombinant carriers comprising these sequences. Also it relates to host cells comprising such nucleic acids, DNA fragments, recombinant DNA molecules and live recombinant carriers. Moreover, the invention relates to proteins encoded by these nucleotide sequences and to their use for the manufacturing of vaccines. The invention also relates to vaccines for combating *Lawsonia intracellularis* infections and methods for the preparation thereof. Finally the invention relates to diagnostic tests for the detection of *Lawsonia intracellularis* antigens and of antibodies against *Lawsonia intracellularis*.




Figure 1.

SEQUENCE LISTING

<110> AKZO Nobel N.V.

<120> Lawsonia intracellularis 101 kD subunit vaccine

<130> 2004.010

<160> 2

<170> PatentIn version 3.2

<210> 1

<211> 2848

<212> DNA

<213> Lawsonia intracellularis

<220>

<221> CDS

<222> (29) .. (2848)

<400> 1

accttaacta aaaaataaaaa agaataatt atg tat aat ata att aat aag cat 52
 Met Tyr Asn Ile Ile Asn Lys His
 1 5

caa atc ata aaa att tta tta ttt tcc tta tgt gtt ttc ttt ttt aca 100
 Gln Ile Ile Lys Ile Leu Leu Phe Ser Leu Cys Val Phe Phe Phe Thr
 10 15 20

ctt aca gaa aaa caa aaa att tat gct gca gac gtc ttt ttt gag ggc 148
 Leu Thr Glu Lys Gln Lys Ile Tyr Ala Ala Asp Val Phe Phe Glu Gly
 25 30 35 40

aga acc gaa acc tta atc aat gta aac aaa cca ttt gat tct ttt ttt 196
 Arg Thr Glu Thr Leu Ile Asn Val Asn Lys Pro Phe Asp Ser Phe Phe
 45 50 55

gga ggt tct gac tct aca ata gga acc ctt gaa aca gga cct act aat 244
 Gly Gly Ser Asp Ser Thr Ile Gly Thr Leu Glu Thr Gly Pro Thr Asn
 60 65 70

ctt acc ttc aca aca gta gga gcc ttc cgc aat tct gtt ttc aga att 292
 Leu Thr Phe Thr Thr Val Gly Ala Phe Arg Asn Ser Val Phe Arg Ile
 75 80 85

att ggt ggt ggt agg tct agt ttt aac aac cca aat aca gtt aaa ggc 340
 Ile Gly Gly Gly Arg Ser Ser Phe Asn Asn Pro Asn Thr Val Lys Gly
 90 95 100

aat gtt act cta act gtt tat aat act gat gta gaa aga ata att ggt 388
 Asn Val Thr Leu Thr Val Tyr Asn Thr Asp Val Glu Arg Ile Ile Gly
 105 110 115 120

gca ggt atc agc aat aga gga ctt gta acc gtt act ggc tca gta aat 436
 Ala Gly Ile Ser Asn Arg Gly Leu Val Thr Val Thr Gly Ser Val Asn
 125 130 135

atg aag cta gaa aat gtt tct gtt act aga gga att tat ggt ggt gtc 484
 Met Lys Leu Glu Asn Val Ser Val Thr Arg Gly Ile Tyr Gly Gly Val
 140 145 150

tat act caa aat gga cat gta cta ggc tct atc aac atg cat ttg aaa 532
 Tyr Thr Gln Asn Gly His Val Leu Gly Ser Ile Asn Met His Leu Lys
 155 160 165

aac gtc caa act cca cta tta ata ggt tct gga gta agc aat gga cct 580

Asn Val Gln Thr Pro Leu Leu Ile Gly Ser Gly Val Ser Asn Gly Pro	
170 175 180	
aat cgt att act gta aat gga gac ata aac att gat gtt gaa gac tct	628
Asn Arg Ile Thr Val Asn Gly Asp Ile Asn Ile Asp Val Glu Asp Ser	
185 190 195 200	
agg att caa tat gta aac att aca gga gaa gta gat gca ggg ata aaa	676
Arg Ile Gln Tyr Val Asn Ile Thr Gly Glu Val Asp Ala Gly Ile Lys	
205 210 215	
gga aat gct act cta act gta aaa aaa tct act gtt gag ctt ata aac	724
Gly Asn Ala Thr Leu Thr Val Lys Lys Ser Thr Val Glu Leu Ile Asn	
220 225 230	
tct ggt aga ggt aat atc tta ggt aat ctc aaa ata tct ata gca gat	772
Ser Gly Arg Gly Asn Ile Leu Gly Asn Leu Lys Ile Ser Ile Ala Asp	
235 240 245	
tca aat ata agg ggg tta tca cca gta gac ttt ggt tct tca gta tat	820
Ser Asn Ile Arg Gly Leu Ser Pro Val Asp Phe Gly Ser Ser Val Tyr	
250 255 260	
ggg gac aca tct ata aat gta att aat tct cag att aat gat att act	868
Gly Asp Thr Ser Ile Asn Val Ile Asn Ser Gln Ile Asn Asp Ile Thr	
265 270 275 280	
ctt ata cca agg gct ggt gga atg ctt gta ggt cct gtt acc cta gat	916
Leu Ile Pro Arg Ala Gly Gly Met Leu Val Gly Pro Val Thr Leu Asp	
285 290 295	
atc aca agc agt act ata caa aat ata caa tgt ggg cct gtc agt caa	964
Ile Thr Ser Ser Thr Ile Gln Asn Ile Gln Cys Gly Pro Val Ser Gln	
300 305 310	
aat aat caa ctt aac aca cta aat gta act gtt aat act agt aac att	1012
Asn Asn Gln Leu Asn Thr Leu Asn Val Thr Val Asn Thr Ser Asn Ile	
315 320 325	
act aac tta aac ctt ggt agt gtc gaa ggt cat aca ata tca act aca	1060
Thr Asn Leu Asn Leu Gly Ser Val Glu Gly His Thr Ile Ser Thr Thr	
330 335 340	
gca act gtt act gat agt aat att act aac ctt aat gtc gga acc ttc	1108
Ala Thr Val Thr Asp Ser Asn Ile Thr Asn Leu Asn Val Gly Thr Phe	
345 350 355 360	
aat gga ctt gga gta act gag aat gcc tct gta atc att aat agt ggc	1156
Asn Gly Leu Gly Val Thr Glu Asn Ala Ser Val Ile Ile Asn Ser Gly	
365 370 375	
aat att act aac ctt aat gtc gga act aat gta ata gct gca gcc aca	1204
Asn Ile Thr Asn Leu Asn Val Gly Thr Asn Val Ile Ala Ala Ala Thr	
380 385 390	
act att aat tcc tct gcg acc ata cac gac gga ctt att gca aac ctt	1252
Thr Ile Asn Ser Ser Ala Thr Ile His Asp Gly Leu Ile Ala Asn Leu	
395 400 405	
acc tta ggc tca caa ggt aat ggt cgt act atg ata gct aca gca aat	1300
Thr Leu Gly Ser Gln Gly Asn Gly Arg Thr Met Ile Ala Thr Ala Asn	
410 415 420	
gtt aat ggt gga act att gga tta tta act atg ggt tca gaa aac ttc	1348
Val Asn Gly Gly Thr Ile Gly Leu Leu Thr Met Gly Ser Glu Asn Phe	
425 430 435 440	
ata cca ggc aca aga cca att act gaa tta gca ata cta aac atg tct	1396

Ile	Pro	Gly	Thr	Arg	Pro	Ile	Thr	Glu	Leu	Ala	Ile	Leu	Asn	Met	Ser	
				445					450					455		
ggt	gga	tta	att	gaa	aga	att	atc	gta	ggt	aat	gcc	aac	tct	tca	acc	1444
Gly	Gly	Leu	Ile	Glu	Arg	Ile	Ile	Val	Gly	Asn	Ala	Asn	Ser	Ser	Thr	
			460					465					470			
ata	aac	ttt	act	cct	ggg	aag	aga	tca	att	gta	aaa	aca	ata	aat	ggt	1492
Ile	Asn	Phe	Thr	Pro	Gly	Lys	Arg	Ser	Ile	Val	Lys	Thr	Ile	Asn	Gly	
		475					480					485				
cca	gaa	ctt	cca	tat	tta	gtt	aac	ata	caa	aaa	ggt	gct	atg	aca	caa	1540
Pro	Glu	Leu	Pro	Tyr	Leu	Val	Asn	Ile	Gln	Lys	Gly	Ala	Met	Thr	Gln	
	490					495					500					
tgg	ggc	act	aaa	aat	atg	ccc	ttt	tta	ttg	gat	aca	aga	aat	tta	atc	1588
Trp	Gly	Thr	Lys	Asn	Met	Pro	Phe	Leu	Leu	Asp	Thr	Arg	Asn	Leu	Ile	
505					510					515					520	
ttg	tcc	gga	act	ctg	att	acc	tca	aat	att	caa	cta	gct	gat	tta	tct	1636
Leu	Ser	Gly	Thr	Leu	Ile	Thr	Ser	Asn	Ile	Gln	Leu	Ala	Asp	Leu	Ser	
				525					530					535		
ata	acc	aat	cta	ttt	gtt	gct	aat	ggc	ggt	aca	cta	gta	cct	aga	aaa	1684
Ile	Thr	Asn	Leu	Phe	Val	Ala	Asn	Gly	Gly	Thr	Leu	Val	Pro	Arg	Lys	
			540					545					550			
tta	ata	cct	ggg	aac	caa	cct	gtt	ata	cag	ttt	ctt	gga	ggt	cct	caa	1732
Leu	Ile	Pro	Gly	Asn	Gln	Pro	Val	Ile	Gln	Phe	Leu	Gly	Gly	Pro	Gln	
		555					560					565				
tca	ctc	tta	gtt	atc	cat	caa	cca	tta	aaa	gta	aat	tta	agc	tta	tca	1780
Ser	Leu	Leu	Val	Ile	His	Gln	Pro	Leu	Lys	Val	Asn	Leu	Ser	Leu	Ser	
	570					575					580					
cca	aaa	ctt	att	gga	agt	agc	atg	gtg	cca	ctt	gct	ttt	gtc	tct	caa	1828
Pro	Lys	Leu	Ile	Gly	Ser	Ser	Met	Val	Pro	Leu	Ala	Phe	Val	Ser	Gln	
585					590					595					600	
tct	ttt	tca	tca	cca	gat	ctt	ttt	gtt	aaa	caa	act	aga	agt	ggt	ctc	1876
Ser	Phe	Ser	Ser	Pro	Asp	Leu	Phe	Val	Lys	Gln	Thr	Arg	Ser	Gly	Leu	
				605					610					615		
att	tgg	agt	gat	ctt	gag	ttt	gat	cca	aca	aca	tct	att	tgg	tat	gtt	1924
Ile	Trp	Ser	Asp	Leu	Glu	Phe	Asp	Pro	Thr	Thr	Ser	Ile	Trp	Tyr	Val	
			620					625					630			
aat	aat	atc	caa	gca	tct	caa	gat	ttt	tac	tct	ttc	tct	att	gct	cgt	1972
Asn	Asn	Ile	Gln	Ala	Ser	Gln	Asp	Phe	Tyr	Ser	Phe	Ser	Ile	Ala	Arg	
		635					640					645				
gag	act	act	aac	tgg	cta	aga	caa	caa	cat	ata	tgg	act	cta	caa	aac	2020
Glu	Thr	Thr	Asn	Trp	Leu	Arg	Gln	Gln	His	Ile	Trp	Thr	Leu	Gln	Asn	
	650					655					660					
cgt	tca	agt	aaa	ctt	tta	gac	aac	gaa	cat	tat	gga	cta	tgg	ata	aat	2068
Arg	Ser	Ser	Lys	Leu	Leu	Asp	Asn	Glu	His	Tyr	Gly	Leu	Trp	Ile	Asn	
665					670					675					680	
gtt	caa	ggt	gga	cat	gaa	agt	ctt	gat	act	tct	att	ggt	agc	aaa	gca	2116
Val	Gln	Gly	Gly	His	Glu	Ser	Leu	Asp	Thr	Ser	Ile	Gly	Ser	Lys	Ala	
				685					690					695		
aaa	atg	cca	tgg	ata	atg	gca	aca	gca	gga	tat	gac	tat	ctt	caa	caa	2164
Lys	Met	Pro	Trp	Ile	Met	Ala	Thr	Ala	Gly	Tyr	Asp	Tyr	Leu	Gln	Gln	
			700					705					710			
cta	cca	agg	tta	gat	atg	aaa	gcc	ctt	tat	ggt	ctt	gct	ttt	ggt	gct	2212

Leu Pro Arg Leu Asp Met Lys Ala Leu Tyr Gly Leu Ala Phe Gly Ala
 715 720 725
 tct aaa ggt aaa agt aaa tgg tct agc gtc aac tct aca aaa aat gat 2260
 Ser Lys Gly Lys Ser Lys Trp Ser Ser Val Asn Ser Thr Lys Asn Asp
 730 735 740
 gct gag cta ggt atg gtt agt ggt tat gta ggt ctt atc cat aac aaa 2308
 Ala Glu Leu Gly Met Val Ser Gly Tyr Val Gly Leu Ile His Asn Lys
 745 750 755 760
 act ggg ctc tat agt aca ttg acc tta caa ctt gcg tct agt aaa tta 2356
 Thr Gly Leu Tyr Ser Thr Leu Thr Leu Gln Leu Ala Ser Ser Lys Leu
 765 770 775
 cat act aat tct aca ggg ttc tat aga aat ttt aaa tgg aca gaa aca 2404
 His Thr Asn Ser Thr Gly Phe Tyr Arg Asn Phe Lys Trp Thr Glu Thr
 780 785 790
 act cca aca gaa gca ctt gaa ctt gga tgg aaa tac act ttc aac aac 2452
 Thr Pro Thr Glu Ala Leu Glu Leu Gly Trp Lys Tyr Thr Phe Asn Asn
 795 800 805
 ggt att aaa atg aat cct cgt gga caa ctt att ttt gaa caa aca tct 2500
 Gly Ile Lys Met Asn Pro Arg Gly Gln Leu Ile Phe Glu Gln Thr Ser
 810 815 820
 aaa cac cat ttt gat tta gga att caa aat gat aag gct ata tta gat 2548
 Lys His His Phe Asp Leu Gly Ile Gln Asn Asp Lys Ala Ile Leu Asp
 825 830 835 840
 aaa agc cag tta ata aca agt tct ctt ggt att acc gtt gaa tat aag 2596
 Lys Ser Gln Leu Ile Thr Ser Ser Leu Gly Ile Thr Val Glu Tyr Lys
 845 850 855
 cta cca gtt acc aca cct att aat ctt tat gct ggt att gaa agg ata 2644
 Leu Pro Val Thr Thr Pro Ile Asn Leu Tyr Ala Gly Ile Glu Arg Ile
 860 865 870
 aaa ggt cag tct gga aac ttt gca att agt tcc cag agc ctt caa atg 2692
 Lys Gly Gln Ser Gly Asn Phe Ala Ile Ser Ser Gln Ser Leu Gln Met
 875 880 885
 aag ttc aag cat gac aat gat aca agt gta gtt aga gca aca ata ggt 2740
 Lys Phe Lys His Asp Asn Asp Thr Ser Val Val Arg Ala Thr Ile Gly
 890 895 900
 aca aat ata tta ttg gga gaa cat ttt aat att cac tgt gat ata ttt 2788
 Thr Asn Ile Leu Leu Gly Glu His Phe Asn Ile His Cys Asp Ile Phe
 905 910 915 920
 gga gat aaa gga aat gat aaa ggc att ggt ggg caa gca gga ttt aca 2836
 Gly Asp Lys Gly Asn Asp Lys Gly Ile Gly Gly Gln Ala Gly Phe Thr
 925 930 935
 tac aaa ttt taa 2848
 Tyr Lys Phe

<210> 2
 <211> 939
 <212> PRT
 <213> Lawsonia intracellularis
 <400> 2

Met Tyr Asn Ile Ile Asn Lys His Gln Ile Ile Lys Ile Leu Leu Phe

1	5	10	15
Ser	Leu	Cys	Val
20	Phe	Phe	Phe
Thr	Leu	Thr	Glu
25	Lys	Gln	Lys
30	Ile	Tyr	
Ala	Ala	Asp	Val
35	Phe	Phe	Glu
40	Gly	Arg	Thr
45	Glu	Thr	Leu
50	Ile	Asn	Val
55	Asn	Lys	Pro
60	Phe	Asp	Ser
65	Phe	Gly	Gly
70	Ser	Asp	Ser
75	Thr	Ile	Gly
80	Thr	Val	Gly
85	Ala		
90	Phe	Arg	Asn
95	Ser	Ser	Phe
100	Asn	Asn	Pro
105	Asn	Thr	Val
110	Lys	Gly	Asn
115	Val	Thr	Leu
120	Thr	Val	Tyr
125	Asn	Arg	Gly
130	Leu	Glu	Asn
135	Val	Ser	Val
140	Met	Lys	Leu
145	Tyr	Thr	Gln
150	Val	Tyr	Asn
155	Gly	Gly	Val
160	Ile	Tyr	Gly
165	Met	His	Leu
170	Lys	Asn	Val
175	Gln	Thr	Pro
180	Leu	Leu	Ile
185	Asp	Gly	Asn
190	Val	Thr	Ile
195	Asn	Ile	Thr
200	Arg	Ile	Gln
205	Tyr	Val	Asn
210	Val	Asp	Ala
215	Gly	Ile	Lys
220	Gly	Asn	Ala
225	Thr	Leu	Thr
230	Val	Glu	Leu
235	Ile	Asn	Ser
240	Gly	Arg	Gly
245	Asn	Ile	Arg
250	Gly	Leu	Ser
255	Pro		
260	Val	Asp	Phe
265	Gly	Asp	Thr
270	Ser	Ile	Asn
	Val	Ile	
	Met		

Asn Ser Gln Ile Asn Asp Ile Thr Leu Ile Pro Arg Ala Gly Gly Met

275	280	285
Leu Val Gly Pro Val Thr	Leu Asp Ile Thr Ser Ser Thr Ile Gln Asn	
290	295	300
Ile Gln Cys Gly Pro Val Ser Gln Asn Asn Gln Leu Asn Thr Leu Asn		
305	310	315
Val Thr Val Asn Thr Ser Asn Ile Thr Asn Leu Asn Leu Gly Ser Val		
	325	330
Glu Gly His Thr Ile Ser Thr Thr Ala Thr Val Thr Asp Ser Asn Ile		
	340	345
Thr Asn Leu Asn Val Gly Thr Phe Asn Gly Leu Gly Val Thr Glu Asn		
	355	360
Ala Ser Val Ile Ile Asn Ser Gly Asn Ile Thr Asn Leu Asn Val Gly		
	370	375
Thr Asn Val Ile Ala Ala Ala Thr Thr Ile Asn Ser Ser Ala Thr Ile		
385	390	395
His Asp Gly Leu Ile Ala Asn Leu Thr Leu Gly Ser Gln Gly Asn Gly		
	405	410
Arg Thr Met Ile Ala Thr Ala Asn Val Asn Gly Gly Thr Ile Gly Leu		
	420	425
Leu Thr Met Gly Ser Glu Asn Phe Ile Pro Gly Thr Arg Pro Ile Thr		
	435	440
Glu Leu Ala Ile Leu Asn Met Ser Gly Gly Leu Ile Glu Arg Ile Ile		
	450	455
Val Gly Asn Ala Asn Ser Ser Thr Ile Asn Phe Thr Pro Gly Lys Arg		
465	470	475
Ser Ile Val Lys Thr Ile Asn Gly Pro Glu Leu Pro Tyr Leu Val Asn		
	485	490
Ile Gln Lys Gly Ala Met Thr Gln Trp Gly Thr Lys Asn Met Pro Phe		
	500	505
Leu Leu Asp Thr Arg Asn Leu Ile Leu Ser Gly Thr Leu Ile Thr Ser		
	515	520
Asn Ile Gln Leu Ala Asp Leu Ser Ile Thr Asn Leu Phe Val Ala Asn		
	530	535
Gly Gly Thr Leu Val Pro Arg Lys Leu Ile Pro Gly Asn Gln Pro Val		

545		550		555		560
Ile Gln Phe Leu Gly Gly Pro Gln Ser Leu Leu Val Ile His Gln Pro	565			570		575
Leu Lys Val Asn Leu Ser Leu Ser Pro Lys Leu Ile Gly Ser Ser Met	580		585		590	
Val Pro Leu Ala Phe Val Ser Gln Ser Phe Ser Ser Pro Asp Leu Phe	595		600		605	
Val Lys Gln Thr Arg Ser Gly Leu Ile Trp Ser Asp Leu Glu Phe Asp	610		615		620	
Pro Thr Thr Ser Ile Trp Tyr Val Asn Asn Ile Gln Ala Ser Gln Asp	625		630		635	640
Phe Tyr Ser Phe Ser Ile Ala Arg Glu Thr Thr Asn Trp Leu Arg Gln		645		650		655
Gln His Ile Trp Thr Leu Gln Asn Arg Ser Ser Lys Leu Leu Asp Asn		660		665		670
Glu His Tyr Gly Leu Trp Ile Asn Val Gln Gly Gly His Glu Ser Leu	675		680		685	
Asp Thr Ser Ile Gly Ser Lys Ala Lys Met Pro Trp Ile Met Ala Thr	690		695		700	
Ala Gly Tyr Asp Tyr Leu Gln Gln Leu Pro Arg Leu Asp Met Lys Ala	705		710		715	720
Leu Tyr Gly Leu Ala Phe Gly Ala Ser Lys Gly Lys Ser Lys Trp Ser		725		730		735
Ser Val Asn Ser Thr Lys Asn Asp Ala Glu Leu Gly Met Val Ser Gly		740		745		750
Tyr Val Gly Leu Ile His Asn Lys Thr Gly Leu Tyr Ser Thr Leu Thr	755		760		765	
Leu Gln Leu Ala Ser Ser Lys Leu His Thr Asn Ser Thr Gly Phe Tyr	770		775		780	
Arg Asn Phe Lys Trp Thr Glu Thr Thr Pro Thr Glu Ala Leu Glu Leu	785		790		795	800
Gly Trp Lys Tyr Thr Phe Asn Asn Gly Ile Lys Met Asn Pro Arg Gly		805		810		815
Gln Leu Ile Phe Glu Gln Thr Ser Lys His His Phe Asp Leu Gly Ile						

820

825

830

Gln Asn Asp Lys Ala Ile Leu Asp Lys Ser Gln Leu Ile Thr Ser Ser
 835 840 845

Leu Gly Ile Thr Val Glu Tyr Lys Leu Pro Val Thr Thr Pro Ile Asn
 850 855 860

Leu Tyr Ala Gly Ile Glu Arg Ile Lys Gly Gln Ser Gly Asn Phe Ala
 865 870 875 880

Ile Ser Ser Gln Ser Leu Gln Met Lys Phe Lys His Asp Asn Asp Thr
 885 890 895

Ser Val Val Arg Ala Thr Ile Gly Thr Asn Ile Leu Leu Gly Glu His
 900 905 910

Phe Asn Ile His Cys Asp Ile Phe Gly Asp Lys Gly Asn Asp Lys Gly
 915 920 925

Ile Gly Gly Gln Ala Gly Phe Thr Tyr Lys Phe
 930 935